Allergy Therapeutics PLC 2024 AR2
The report highlights Allergy Therapeutics' financial and clinical progress during the fiscal year 2024, emphasizing its recovery and cost-saving initiatives. Key achievements include the successful completion of the pivotal Phase III G306 trial for the Grass MATA MPL candidate and the progression of the Phase I/IIa PROTECT trial for the VLP Peanut vaccine. On the environmental front, the company continued to capture emissions data under SECR regulations, reporting a total of 2,687 tonnes of CO2e, an 11% reduction from the previous year. Additionally, the company advanced the development of its Energy Centre in Worthing to establish energy independence and strengthen business continuity.
Company: Allergy Therapeutics PLC
Sector: Health Care
Country: United Kingdom
Year: 2024
Type: AR2
Pages: 120
Allergy Therapeutics PLC
Annual Report And Accounts
The report highlights Allergy Therapeutics' financial and clinical progress during the fiscal year 2024, emphasizing its recovery and cost-saving initiatives. Key achievements include the successful completion of the pivotal Phase III G306 trial for the Grass MATA MPL candidate and the progression of the Phase I/IIa PROTECT trial for the VLP Peanut vaccine. On the environmental front, the company continued to capture emissions data under SECR regulations, reporting a total of 2,687 tonnes of CO2e, an 11% reduction from the previous year. Additionally, the company advanced the development of its Energy Centre in Worthing to establish energy independence and strengthen business continuity.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Women on Board
Employees